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Transforming growth factor beta and progression of renal dis-
ease. End-stage renal disease (ESRD) is more frequent in
African Americans compared to whites. Many factors may be
responsible, including genetic differences, increased prevalence
of risk factors, and socioeconomic factors; however, to date,
these proposed genetic or environmental factors have not pro-
vided a satisfactory explanation for the increased risk of ESRD
in African Americans. Because renal fibrosis is a correlate of
progressive renal failure and a dominant feature of ESRD,
and because transforming growth factor beta 1 (TGF-1) can
induce fibrosis and renal insufficiency, we explored the hypoth-
esis that TGF-1 hyperexpression is more frequent in African
Americans compared to whites. We tested our hypotheses by
measuring TGF-1 levels in African Americans and white pa-
tients with ESRD, hypertension, and in normal patients. In
hypertensive and normal patients, we also evaluated TGF-1
mRNA levels, and TGF-1 DNA polymorphisms. We demon-
strated that circulating levels of TGF-1 are higher in African
American ESRD patients, hypertensive patients, and normal
control patients compared to their white counterparts. We also
reported that TGF-1 mRNA levels are higher in hypertensives
compared to normotensives. Our preliminary genetic analyses
suggest that TGF-1 DNA polymorphisms may distinguish hy-
pertensives from normotensives, and our laboratory is cur-
rently investigating racial differences in TGF-1 DNA poly-
morphisms. Our observations of hyperexpression of TGF-1
in African Americans suggest a mechanism for the increased
prevalence of renal failure and hypertensive target organ dam-
age in this population.
End-stage renal disease (ESRD) is a devastating medi-
cal illness of extraordinary personal suffering and soci-
etal costs. The incidence and prevalence of ESRD has
been rising steadily, due in large part to the aging of
the population and the increased prevalence of type 2
diabetes, the leading cause of ESRD in the United States
[1]. The incidence of ESRD in the United States in 2000
was 93,635, and the estimated Medicare ESRD point
prevalence in 2000 was over 400,000 patients. The ad-
justed death rate during the first year of ESRD is 24%,
despite renal replacement therapy. The expected re-
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maining lifetime for ESRD patients of 45 to 54 years of
age and 55 to 64 years of age (the largest group of ESRD
patients are in the 45 to 54 age group) is 6.9 years and 5.3
years, respectively. The three most common attributed
causes of ESRD in the United States are diabetes (39.4%
of whites and 38.0% of African American patients), hy-
pertension (22.5% of whites and 35.5% of African Amer-
ican patients), and glomerulonephritis (11.7% of whites
and 9.0% of African American patients) [1].
Renal disease in African Americans
ESRD is four times more frequent in African Ameri-
cans compared to whites [1]. Whereas 12.7% of the
United States population is African American, 32% of
ESRD cases are African Americans. The increased inci-
dence in African Americans of the three most common
causes of ESRD fails to explain the excess burden, since
the age- and gender-adjusted incidence of ESRD due to
hypertension, diabetes, or glomerulonephritis is 3- to
10-fold higher in African Americans [1]. The increased
prevalence of hypertensive nephrosclerosis in African
Americans is particularly noteworthy. It has been argued
that nephrosclerosis is a primary renal disorder, rather
than a direct consequence of poorly controlled blood
pressure, and that genetically determined risk factors, in
addition to hypertension, may be responsible. Data from
two major clinical trials, the Multiple Risk Factor Inter-
vention Trial (MRFIT) [2], and the Modification of Diet
in Renal Disease (MDRD) study [3], as well as the recent
Glomerular Disease Collaborative Network [4], have all
demonstrated that renal disease progresses more rapidly
in African Americans. To date, the proposed genetic
and or environmental factors have failed to yield a unify-
ing and mechanism-based explanation for the heightened
risk of ESRD in African Americans.
Biologic actions and experimental data supporting
a pathogenetic role for TGF-1 in progressive
renal disease
Transforming growth factor 1 (TGF-1) is a 25 kD
homodimeric protein secreted by several cell types, in-
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cluding renal cells. It is a fibrogenic cytokine [5, 6] and
is secreted in an inactive (latent) form and requires pro-
cessing before it is biologically active [7]. TGF-1 plays
a major role in regulating biologic processes such as cell
growth, differentiation, development, tissue repair, and
apoptosis. TGF-1 promotes the accumulation of extra-
cellular matrix by increasing expression of extracellular
matrix genes and by inhibiting production of proteins
responsible for breaking down extracellular matrix [8].
Tissue fibrosis due to increased accumulation of extracel-
lular matrix is a feature of several types of renal disease,
and there is abundant data that overproduction of active
TGF-1 is responsible. In rat models of glomerulonephri-
tis, intrarenal expression of TGF-1 was associated with
increased extracellular matrix and anti-TGF-1 antibod-
ies prevented matrix assembly [9]. In a diabetic mouse
model, antibodies directed at TGF-1 prevented hyper-
glycemia-related increases in TGF-1 mRNA and pre-
vented glomerular hypertrophy [10]. In vivo transfection
of the TGF-1 gene results in glomerulosclerosis [11],
and a TGF-1 antisense oligomer reduces intrarenal ex-
pression of TGF-1 and suppresses extracellular matrix
accumulation in a glomerulonephritis model [12].
Clinical data implicating TGF-1 in renal disease
TGF-1 is hyperexpressed in human glomerular dis-
eases including immunoglobulin A (IgA) nephropathy,
lupus nephritis, focal, and segmental glomerulosclerosis
[13]. There is considerable evidence that increased pro-
duction of TGF-1 plays an important role in the devel-
opment of diabetic nephropathy [14]. We reported that
progressive failure of renal allografts (chronic rejection)
is associated with TGF-1 hyperexpression [15].
TGF-1 and hypertension
Recent data suggest that TGF-1 may have a direct
pathogenic role in elevated blood pressure. TGF-1 stim-
ulates the expression of mRNA encoding endothelin 1
in vascular endothelial cells [16], and also increases renin
release from juxtaglomerular cells in the kidney [17].
TGF-1 and the renin-angiotensin system
Activation of the renin-angiotensin system is an impor-
tant feature of progressive renal disease. Interestingly,
angiotensin II stimulates the production of TGF-1 [17].
TGF-1 neutralizing antibodies, or TGF-1 antisense oli-
gonucleotides block Ang II–mediated stimulation of ex-
tracellular matrix production in the kidney [18]. The
beneficial effects of blocking Ang II production for clini-
cal renal disease have been well demonstrated, and it is
likely that these benefits are in part due to decreasing
TGF-1 effects in the kidney.
In view of the abundant experimental evidence for
the role of TGF-1 in the progression of renal disease, we
explored the hypothesis that hyperexpression of TGF-1
is a feature of patients with end-stage renal disease and
those with hypertension. We also hypothesized that hy-
perexpression of TGF-1 is more frequent in African
Americans compared with whites, and may in part be
responsible for the increased burden of kidney disease
in this population. We also suggested that hyperexpres-
sion of TGF-1 might be genetically determined because
DNA polymorphisms in codon 25 of the TGF-1 gene
have been associated with hypertension [19], and codon
10 polymorphisms have been associated with lung fibro-
sis [20].
METHODS
End-stage renal disease patient population
Fifty-two African American and 46 white patients with
ESRD treated with chronic hemodialysis therapy were
studied for level of expression of TGF-1 protein in their
peripheral blood. Blood was also drawn from 30 healthy
white and 32 healthy African American individuals for
cytokine analysis.
Hypertensive patient population
Hypertensive subjects (N  61) were recruited from
the outpatient clinic at the Hypertension Division of Weill
Medical College of Cornell University. Subjects were in-
cluded if blood pressure was greater than 140/90 mm Hg
on at least two occasions if patients were off medications.
For those on antihypertensive medications, records were
reviewed to ascertain the validity of the diagnosis of hyper-
tension. Normal subjects (N  90) were recruited from
hospital employees.
TGF-1 profiling
TGF-1 profiling was performed, including measure-
ment of serum TGF-1 levels using a solid-phase TGF-1
specific sandwich enzyme-linked immunosorbent assay
(ELISA) (Promega, Madison, WI, USA) [21], quantifi-
cation of mRNA in peripheral blood mononuclear cells
(PBMC) using competitive reverse transcription-poly-
merase chain reaction (RT-PCR) as previously described
[22], and genotyping of codon 25 of the TGF-1 beta gene
using ampflication-refractory mutation system PCR, an
allele-specific technique to detect single nucleotide poly-
morphisms [22].
RESULTS
Circulating levels of TGF-1 protein are higher in
African American ESRD patients
African American and white patients were similar with
respect to age, sex, years on dialysis, and concentrations
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Table 1. Clinical and laboratory features of end-stage
renal disease (ESRD) patients
African
American White
Variable (N  52) (N  46) P valuea
Age 56.92.1b 612.3 0.20
Gender M/F 24/28 27/19 0.23
Years on hemodialysis 60.9 40.7 0.15
Sodium mmol/L 1380.5 1390.4 0.70
Potassium mmol/L 4.90.1 5.00.09 0.59
Chloride mmol/L 990.5 990.5 0.65
CO2 mmol/L 230.5 230.5 0.86
Glucose mg/dL 11711 1198 0.87
Calcium mg/dL 9.30.1 9.50.1 0.76
Phosphate mg/dL 6.20.3 5.70.3 0.23
AST/SGPT units/L 162 152 0.93
Alkaline phosphatase units/L 15615 12614 0.11
Albumin g/dL 3.90.06 4.10.06 0.07
Cholesterol mg/dL 1714 1735 0.79
Hematocrit 33.50.5 33.20.5 0.51
Urea reduction ratio % 661 650.9 0.52
Urea nitrogen mg/dL 662 743 0.06
Creatinine mg/dL 11.00.4 9.20.4 0.004
Systolic pressure mm Hg 1523 1413 0.03
Diastolic pressure mm Hg 782 712 0.004
Mean arterial pressure mm Hg 1032 942 0.004
aP values based on Student t test for continuous variables and on Fisher exact
test for categorical variables
b Mean  SEM
of electrolytes (Table 1). Plasma creatinine concentra-
tion and blood pressure were higher in African American
compared to whites (Table 1). TGF-1 protein concentra-
tion was detected in the peripheral blood of all patients,
and was higher in the African American compared to
the whites (Fig. 1). The mean SEM TGF-1 concentra-
tion was higher in African American ESRD patients
(207  10 ng/mL, N  52) compared to their white
counterparts (137 8 ng/mL, N 46) (P 0.0001, t test).
The association between TGF-1 levels and race, and
the correlation between TGF-1 levels and other clinical
and biochemical variables measured in the ESRD co-
hort, were determined using the correlation analysis pro-
cedure of SAS (Cary, NC, USA) [23]. This analysis dem-
onstrated that the association between TGF-1 levels
and race was significant (correlation coefficient, r 
0.460, P  0.0001); TGF-1 levels were also a significant
correlate of mean arterial pressure (r 0.212, P 0.035).
In contrast, additional variables such as age, sex, albu-
min, cholesterol, glucose, hematocrit, creatinine, blood
urea nitrogen, urea reduction ratio, and years of dialysis
therapy were not significant correlates of TGF-1 levels.
Race, in addition to TGF-1 levels, was also significantly
associated with mean arterial pressure (r  0.282, P 
0.004) and creatinine (r  0.288, P  0.004).
Multivariate linear regression model of TGF-1 levels
in ESRD patients
In a multivariate linear regression model, TGF-1 was
considered as the dependent variable, and race and five
Fig. 1. Differential level of expression of transforming growth factor
beta 1 (TGF-1) protein in African American ESRD patients and white
ESRD patients. (A ) The mean SEM TGF-1 protein level was 207 
10 ng/mL in African American ESRD patients (N  52) and 137  8
ng/mL in white ESRD patients (N 46). (B) The frequency distribution
of TGF-1 levels in the ESRD patients, distinguished by race. TGF-1
values (96%) from African American ESRD patients were within 2 SD
of the mean value, and the coefficient of skewness and the coefficient
of kurtosis were 0.20 and 0.24, respectively; 93% of the TGF-1 values
from white ESRD patients were within 2 SD of the mean value, and
the coefficient of skewness and the coefficient of kurtosis were 0.38 and
0.78, respectively. In view of the normal distribution of TGF-1 values
in the African American as well as white ESRD patients, Student t test
was used to derive the P value shown.
Table 2. In vivo TGF-1 protein levels in hypertensives and normals
TGF-1
Group Race (N ) Diagnosis protein Pa
I African American (18) Hypertension 31214
II African American (39) Normal 2199
III White (48) Hypertension 2399
IV White (50) Normal 1658 0.0001
aP value derived by ANOVA; group I vs. group II, 0.0001; III vs. IV, 0.0001;
I vs. III, 0.0001; II vs. IV, 0.0001.
other variables (sex, age, albumin, cholesterol, glucose)
that did not correlate with each other (by correlation
analysis) were considered as independent variables. This
analysis showed that the race of the ESRD patient is a
significant (P  0.0001) determinant of circulating TGF-
1 protein level.
TGF-1 levels in patients with hypertension
Our investigation of hypertensive and normal patients,
summarized in Table 2, shows that TGF-1 protein levels
are higher in: (1) African American hypertensives com-
pared to African American normal patients (P 0.0001);
(2) white hypertensives compared to white normal pa-
tients (P  0.0001); (3) African American hypertensives
compared to white hypertensives (P  0.0001); and (4)
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Fig. 2. Transforming growth factor 1 (TGF-1) mRNA steady state
levels in hypertensives and normotensives. The mean  SEM TGF-1
mRNA/GAPDH mRNA ratios, calculated after quantification of
mRNA levels in peripheral blood mononuclear cells (PBMC) were
3.35  0.81 and 4.51  0.69 in normotensives (N) and hypertensives
(HT), respectively (P  0.04, Mann-Whitney two-sample test).
African Americans normal patients compared to white
normal patients (P  0.0001).
A multiple regression analysis was used to estimate
the independent effects of race (African Americans vs.
white), diagnosis (hypertension vs. normal), gender, and
age on circulating levels of TGF-1 protein. Race and
diagnosis were both significant predictors of TGF-1 lev-
els (P  0.001; P  0.002, respectively), but gender and
age were not. The findings that race and blood pressure
were independently related to TGF-1 levels, but not
age and gender in this study of hypertensives and normo-
tensives, exactly parallel our results in ESRD.
TGF-1 mRNA in hypertensive and
normotensive subjects
Quantification of TGF-1 mRNA levels in PBMC ob-
tained from hypertensive patients and normotensive con-
trol patients showed that TGF-1 mRNA was expressed
at a significantly higher level in PBMC of hypertensive
patients (N 55) compared with PBMC of normotensive
control patients (N 41) (P 0.04, Mann-Whitney two-
sample test) (Fig. 2). In a fashion similar to TGF-1
protein levels, African American hypertensives had the
highest level of TGF-1 mRNA. However, there was no
significant difference in the TGF-1 mRNA steady-state
levels between African American hypertensives and
white hypertensives.
Table 3. TGF-1 codon 25 genotypes in hypertensives
and normotensives
Diagnosis (N ) G/G G/C
Hypertensive (71) 92% (65) 8% (6)
Normotensive (57) 86% (49) 14% (8)
Basis for transforming growth factor hyperexpression
We have begun to explore the basis of TGF-1 hyper-
expression in African Americans. A potential mechanism
for heterogeneity in TGF-1 levels is polymorphism in
the TGF-1 gene. Seven single nucleotide polymor-
phisms in human TGF-1 genes have been identified,
with strong linkage disequilibrium among six of the seven
polymorphisms [19] ARMS-PCR, an allele-specific PCR,
is a powerful new tool for the ready detection of single
nucleotide polymorphisms [24, 25]. Based on the princi-
ple that oligonucleotides that are complementary to a
target DNA sequence except for a mismatched 3 termi-
nus will not function as PCR primers, we have designed
and synthesized oligonucleotide primers for the identifi-
cation of TGF-1 codon 25 genotype and alleles. We
have genotyped 128 individuals for TGF-1 codon 25,
and the results are shown in Table 3. The frequency of
GG genotype was higher in hypertensive (92%) com-
pared to normal patients (86%). The frequency of GC
genotype in our white normal patients is similar to earlier
studies of white patients [19]. Our finding that the GG
frequency is higher in hypertensives compared to normo-
tensives is also in accord with the ECTIM Study of 629
whites, in which the presence of a proline allele in codon
25 (C proline) was associated with a significantly lower
blood pressure (P  0.002). We are currently investigat-
ing the frequencies of all seven polymorphisms in Afri-
can American and white subjects.
CONCLUSION
Our data demonstrate that circulating levels of TGF-1
are higher in African American ESRD patients, hyper-
tensive patients, and normal control patients compared
to their white counterparts. We also report that TGF-1
mRNA levels are higher in hypertensives compared to
normotensives. Our preliminary genetic analyses suggest
that TGF-1 DNA polymorphisms may distinguish hy-
pertensives from normotensives, and our laboratory is
currently investigating racial differences in TGF-1 DNA
polymorphisms.
In view of the potential of TGF-1 to induce renal
fibrosis and progressive renal disease, as well as its associ-
ation with peptides involved in blood pressure regulation
such as endothelin-1 and Ang II, we offer here the hy-
pothesis that heightened TGF-1 expression is a mecha-
nism for the increased prevalence of ESRD in the United
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Fig. 3. Hypothetical model of transforming growth factor beta 1 (TGF-
1) hyperexpression as a contributory factor for progressive renal insuf-
ficiency. In this hypothesis for the pathogenesis of progressive renal
insufficiency, patients expressing high levels of TGF-1 in response to
renal injury are at an increased risk for progression. In this formulation,
TGF-1 expression is engendered by the primary insult (e.g., diabetes),
and progressive renal insufficiency results from the heightened expres-
sion of TGF-1. Abbreviations are: DM, diabetes mellitus; GN, glomeru-
lonephritis; HT, hypertension; ESRD, end-stage renal disease.
States African American population. We propose that
TGF-1 hyperexpression is not necessarily the cause of
renal disease; it is, rather, an important cofactor that
results in accelerated progression of renal failure in sub-
jects with a variety of renal diseases (Fig. 3). Our data
demonstrating higher levels of TGF-1 in African Ameri-
can hypertensives compared with whites also suggests
that TGF-1 may contribute independently to the patho-
genesis of hypertension, or it may contribute to the vas-
cular complications of increased blood pressure. Further
studies exploring polymorphisms in the TGF-1 gene and
their functional consequences might help to resolve the
existing enigma of the increased risk of ESRD in the
United States African American population, as well as
identify a risk factor for progressive renal disease. Fur-
ther studies of additional TGF-1 isoforms, TGF-1 re-
ceptors, and TGF-1 signal transduction may provide
insights into the role of this important cytokine in renal
and hypertensive disease.
Our results have important clinical implications. An-
giotensin II stimulates production of TGF-1 via the
AT-1 receptor, and both angiotensin-converting enzyme
inhibitors and angiotensin receptor antagonists have
been demonstrated to reduce production of TGF-1 in
experimental models. These drugs have also been shown
to lower circulating levels of TGF-1 in patients with
kidney transplants and in those with diabetic nephropa-
thy. Given the evidence for excessive target organ dam-
age in African Americans, and in particular, the in-
creased incidence of ESRD, which may in part be related
to TGF-1 excess, judicious use of ACE inhibitors and
angiotensin receptor antagonists should be considered
in African American hypertensive patients, particularly
when target organ damage is already manifest. In fact,
the AASK Study recently demonstrated the superiority
of ACE inhibitors over calcium channel blockers and
beta-blockers in slowing the progression of hypertensive
nephrosclerosis in African Americans. Lowering blood
pressure, however, is of paramount importance, and
should be a major goal of therapy as well.
Reprint requests to Phyllis August, M.D., M.P.H., 525 East 68th
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